/PRNewswire/ Asieris Pharmaceuticals (688176.SH), a global biopharma company specializing in discovering, developing and commercializing innovative drugs.
Press release - Oslo, Norway, September 15, 2022: Photocure ASA , The Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals has communicated today on the inclusion of Hexvix®. | September 15, 2022
29.08.2022 - Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has entered into a license agreement relating to its preclinical asset, Nepicastat, with Asieris Pharmaceuticals, a biotechnology company headquartered in China. Under the terms of the . Seite 1
/PRNewswire/ Asieris Pharmaceuticals (stock code: 688176.SH), a global biopharma company specializing in discovering and developing innovative drugs for the.